Business
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX: HBP ) ("Helix...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy CollaborationRICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP) (\"Helix\" or the \"Company\"), is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center (\"Moffitt\") for an additional year.To date, Helix and Moffitt have developed a new pancreatic adenocarcinoma mouse model suitable for testing the Company's lead clinical compound L-DOS47 alone or in combination with immunotherapies. Preliminary data includes how L-DOS47 may work with immunotherapy were shown in American Association for Cancer Research (\"AACR\") Annual Meeting 2019. In addition, in September 2019, at the World Molecular Imaging Conference, the Company and Moffitt jointly presented a poster presentation on the pharmacodynamics of targeted urease and checkpoint blockade using Chemical Exchange Saturation Transfer (\"CEST\") and 31P-magnetic resonance spectroscopy (\"31P-MRS\"). The imaging technique is currently being used in the Company's U.S. clinical study in advanced stage pancreatic patients.In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.\"I look forward to expanding the use of L-DOS47 in combination with immunotherapy for future clinical application\", said Dr. Heman Chao, Helix's Chief Executive Officer.About Helix BioPharma Corp.Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. Helix's product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (\"CAR\") based cell therapies. Helix is currently listed on the TSX under the symbol \"HBP\".About L-DOS47L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironme...